Andrewj Armstrong News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Andrewj armstrong. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Andrewj Armstrong Today - Breaking & Trending Today

Adding Olaparib to Abiraterone Does Not Worsen HRQoL in mCRPC

Investigators studied health-related quality of life (HRQoL) and pain outcomes for patients with metastatic prostate cancer (mCRPC) taking olaparib plus abiraterone. ....

North Carolina , United States , Andrewj Armstrong , Merck Sharp Dohme , American Society Of Clinical Oncology , Duke Cancer Institute Center , American Society , Clinical Oncology , Urologic Cancer , Functional Assessment , Cancer Therapy , Prostate Cancer , Brief Pain Inventory Short Form , Merck Sharp ,

Adding Olaparib to Abiraterone Does Not Worsen HRQoL in mCRPC

Investigators studied health-related quality of life (HRQoL) and pain outcomes for patients with metastatic prostate cancer (mCRPC) taking olaparib plus abiraterone. ....

United States , North Carolina , Andrewj Armstrong , Duke Cancer Institute Center , American Society Of Clinical Oncology , American Society , Clinical Oncology , Urologic Cancer , Functional Assessment , Cancer Therapy , Prostate Cancer , Brief Pain Inventory Short Form ,

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future. ....

North Carolina , United States , Andrewj Armstrong , Ashling Wahner , Duke Cancer Institute In Durham , Duke Cancer Institute , Onclive State , Science Summit , Apple Podcasts , Google Podcasts , Amazon Music , Fda Approval Of Olaparib Plus Abiraterone , Patients With Brca Mutated Metastatic Castration Resistant Prostate Cancer , Duke Cancer Institute , Propel Trial ,

Dr Armstrong on the FDA Approval of Abiraterone/Olaparib Combination in BRCA-mutated mCRPC

Andrew J. Armstrong, MD, MSc, discusses the significance of the FDA approval of olaparib plus abiraterone acetate and prednisone or prednisolone in patients with BRCA-mutated metastatic castration-resistant prostate cancer. ....

Andrewj Armstrong , Duke Cancer Center , Duke Cancer Institute , Olaparib Plus Abiraterone Acetate , Patients With Brca Mutated Metastatic Castration Resistant Prostate Cancer , Propel Trial ,

New drug combo shows promise against prostate cancer in trials

In a phase 3 clinical trial by Pfizer, treatment with talazoparib and enzalutamide lowered the risk of prostate cancer progression or death by 37%. ....

Andrewj Armstrong , Coran Sternberg , Scottt Tagawa , Nicholas Zorko , Duke Cancer Institute Center , Masonic Cancer Center , University Of Minnesota , Urologic Cancers , Weill Cornell Medicine , Medical News Today ,